

26 December 2023

✨ **Exciting News from Cystic Fibrosis Australia!** ✨

As your peak national body, we are thrilled to share a momentous update with our incredible community. It brings us immense joy to announce the extension of Orkambi (lumacaftor/ivacaftor) to patients aged 1 year to less than 2 years has been approved and will be made available on the Pharmaceutical Benefits Scheme (PBS) from January 1st, 2024. This extension opens new doors of hope for our little ones carrying two copies of the F508del mutation.

Previously this treatment was only available on the PBS for patients aged 2 years and older with this mutation.

This ground-breaking development marks a crucial opportunity for approximately 35 children to have access for the first time, to a treatment that holds the potential to transform their quality of life and pave the way for better health outcomes.

We extend our heartfelt gratitude to everyone who has supported our mission. Together, we are making strides towards a brighter future for those affected by cystic fibrosis. Let's continue spreading awareness, fostering support, and making a positive impact on the lives of those in our community.

Warm Regards,

Jo Armstrong

CEO

Cystic Fibrosis Australia